Company Announcement
Receipt of Manufacturing Licence for Ropren®

Further to Solagran’s ASX announcement of 20 February 2008 in which it was stated that the award of Manufacturing Licences for both the prescription pharmaceutical Ropren® and its active ingredient Bioeffective® R was imminent, the Directors of Solagran are pleased to announce that the Ministry of Health of the Russian Federation has now issued these licences.

The Directors believe that based on the attached letter from the General Director of Galenopharm (Solagran’s manufacturing partner in St Petersburg), Ropren® will be available for sale in Russia towards the end of April 2008 after it is officially released. This is now just an administrative formality. In the meantime, the company will officially advise the hospital networks in Moscow and St Petersburg of Ropren’s impending availability.

As was announced on 18 July 2007 when Ropren® was approved as a pharmaceutical and entered into the Russian Pharmacopoeia, supply constraints mean that distribution will initially be limited to Moscow and St Petersburg.

The company is currently working on a number of initiatives to put in place manufacturing capacity sufficient to meet the expected demand from both the remainder of Russia and the CIS countries.

The Directors would like to congratulate all members of the team involved in what has been a long and complex regulatory approval process. Special thanks are due to Mr Tamerlan Aslanbekovich Balaev of Galenopharm, for his tireless efforts throughout the entire regulatory approval process.


For personal use only
ОТКРЫТОЕ АКЦИОНЕРНОЕ ОБЩЕСТВО
ФАРМАЦЕВТИЧЕСКАЯ ФАБРИКА
Санкт-Петербурга

Дом 24-а, ул. Можайского, Санкт-Петербург, 199144, Россия
Тел./факс: (812) 271-2988, 271-5165, 271-4434, 271-6712
E-mail: prim@galenopharm.ru Internet: www.galenopharm.ru

27.02.08 № 4-240-262
На № от

Председателю правления компании «Soilagran Limited»
В. С. Султанову

Уважаемый Вагиф Султанович!

Сообщаем Вам, что для осуществления продажи лекарственного средства необходимо наличие трех документов:
- регистрационного удостоверения
- лицензии на производство
- решения о выпуске

Решение о выпуске выдается Федеральной службой по надзору в сфере здравоохранения и социального развития Росздравнадзора на основании письма Института стандартизации и контроля лекарственных средств ФГУ НЦЭСП о снятии с предварительного контроля. Этим занимается отдел организации государственного контроля производства лекарственных средств Управления организации государственного контроля обращения медицинской продукции и средств реабилитации инвалидов Федеральной службы. Процедура оформления Решения о выпуске занимает 1-1,5 месяца.

Генеральный директор
Т. А. Балаев

Исп. Бадьгина И. Б.
t.(812) 271-48-10
St-Petersburg Pharmaceutical Factory Ltd

27 February 2008
No.4-240-262

V.S. Soultanov
Chairman
Solagran Limited

Dear Vagif Soultanovich,

We advise you that for sale of a therapeutic substance it is required 3 documents:

- registration certificate
- manufacturing license
- official release to market

The official release to market is issued by the Federal Authority for Supervision of Healthcare and Social Development of the Russian Health Inspectorate based on the letter [issued on 15 February and received last week] from the Institute for Standardisation and Control of Therapeutic Substances about release from preliminary control.¹ This is controlled by the Department of State Control of Manufacturing of Therapeutic Substances of the State Authority for Control of Distribution of Medical Products and Products for Rehabilitation of Invalids of the Federal Service.

The release to market will be received in 1-1.5 months.

T. A Balayev
General Director

¹Note. The Institute for Standardisation and Control of Therapeutic Substances is part of the Federal Authority “Scientific Centre for Examination of Substances for Medicinal Use”